ABX-IL8 is a humanized antibody targeting IL-8, which interferes with the tubular formation of human umbilical vein endothelial cells, inhibiting angiogenesis, tumor growth, and metastasis in human melanoma.

ABX-IL8 (100 μg/ml) did not affect the proliferation of A375SM and TXM-13 melanoma cells, but down-regulated the activity of MMP-2 metalloproteinase, which inhibited the invasion of human melanoma cells.
ABX-IL8 (100 μg/ml) directly interferes with tubule formation of human umbilical vein endothelial cells. [1]
ABX-IL8 blocking IL-8 significantly inhibited the expression, activity, and transcription of MMP-2 and MMP-9, resulting in reduced invasion through remodeling the basement membrane in vitro. [2]

In nude mice treated with ABX-IL8 (1 mg/3 times weekly, intrabitoneal injection for 3 weeks) subcutaneously injected with A375SM and TXM-13, results showed that tumor growth of both types of melanoma was significantly inhibited in ABX-IL8-treated mice. [1]

Human

Immobilized Human IL-8 Protein at 2 μg/mL can bind ABX-IL8. The EC50 is 0.1472 μg/mL.

Monoclonal

Unconjugated